Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSO NASDAQ:HCAQ NASDAQ:IKNA NASDAQ:YI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.99-4.8%$1.02$0.71▼$1.61$65.11M1.19145,492 shs98,055 shsHCAQHealthCor Catalio Acquisition$0.80-0.6%$8.72$9.48▼$11.00$17.05MN/A114,974 shs123,510 shsIKNAIkena Oncology$1.26-2.3%$1.29$0.97▼$1.94$62.25M0.5131,087 shs514,949 shsYI111$7.54$7.78$4.15▼$12.60$65.18M0.4424,774 shs2,767 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents+0.97%-6.31%-14.75%+0.97%-7.14%HCAQHealthCor Catalio Acquisition+0.63%+3.34%+11.50%+20.40%-24.06%IKNAIkena Oncology-9.15%-3.73%-8.51%+16.22%-25.22%YI111+1.89%-1.63%-7.14%+0.53%-33.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTSOCytosorbents1.7475 of 5 stars3.51.00.00.02.90.00.6HCAQHealthCor Catalio AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AIKNAIkena Oncology2.7661 of 5 stars3.33.00.00.02.11.71.3YI1110.239 of 5 stars0.02.00.00.01.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 3.00Buy$5.50455.56% UpsideHCAQHealthCor Catalio Acquisition 0.00N/AN/AN/AIKNAIkena Oncology 2.50Moderate Buy$3.00138.10% UpsideYI111 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HCAQ, IKNA, YI, and CTSO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/12/2025YI111Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)6/27/2025YI111Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/25/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/11/2025YI111Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)5/24/2025YI111Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)5/15/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/15/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.005/10/2025YI111Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/2/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/24/2025YI111Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$35.60M1.74N/AN/A$0.20 per share4.95HCAQHealthCor Catalio AcquisitionN/AN/AN/AN/AN/AN/AIKNAIkena Oncology$9.16M6.64N/AN/A$2.61 per share0.48YI111$1.97B0.03N/AN/A($10.43) per share-0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$20.72M-$0.28N/AN/AN/A-41.77%-105.04%-29.18%8/12/2025 (Estimated)HCAQHealthCor Catalio AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AIKNAIkena Oncology-$49.23M-$0.860.00N/AN/AN/A-30.59%-27.55%8/14/2025 (Estimated)YI111-$1.42M-$0.64N/A∞N/A-0.48%N/A-2.45%8/27/2025 (Estimated)Latest HCAQ, IKNA, YI, and CTSO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IKNAIkena Oncology-$0.14N/AN/AN/AN/AN/A8/12/2025Q2 2025CTSOCytosorbents-$0.07N/AN/AN/A$9.79 millionN/A6/19/2025Q1 2025YI111N/A-$0.20N/A-$0.20N/A$486.35 million5/14/2025Q1 2025CTSOCytosorbents-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million5/8/2025Q1 2025IKNAIkena Oncology-$0.21-$0.18+$0.03-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/AHCAQHealthCor Catalio AcquisitionN/AN/AN/AN/AN/AIKNAIkena OncologyN/AN/AN/AN/AN/AYI111N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents0.982.612.30HCAQHealthCor Catalio AcquisitionN/A0.480.48IKNAIkena OncologyN/A13.3113.31YI111N/A1.140.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%HCAQHealthCor Catalio Acquisition84.18%IKNAIkena Oncology75.00%YI11121.32%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents7.30%HCAQHealthCor Catalio AcquisitionN/AIKNAIkena Oncology5.94%YI11143.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.61 million58.04 millionOptionableHCAQHealthCor Catalio Acquisition221.31 millionN/ANot OptionableIKNAIkena Oncology7048.26 million45.39 millionNot OptionableYI1111,2388.64 million4.85 millionOptionableHCAQ, IKNA, YI, and CTSO HeadlinesRecent News About These CompaniesAgenda 111 projects at varied completion stages – ISSER clarifiesJuly 16 at 7:04 PM | msn.comMonsoon rains kill 111 as Indus river floods spread furtherJuly 16 at 7:04 PM | msn.comMonsoon Rains, Flash Floods Leave 111 Dead, 212 Injured across PakistanJuly 16 at 7:04 PM | tasnimnews.comTPakistan: 15 More Dead As Torrential Rain, Flash Floods Continue To Wreak Havoc; Death Toll Hits 111July 16 at 7:04 PM | msn.comDBR Bites #111: 5X5 And Man Alive...We’ve Got Hoops To Talk About!July 16 at 7:04 PM | msn.comPenthouse at 111 Murray sells for $17M offJuly 16 at 7:04 PM | therealdeal.comTTDOT says Hwy. 111 ramp will be closed through mid-AugustJuly 16 at 7:04 PM | herald-citizen.comHFirefighters working 111-acre fire in remote part of southwest La Plata CountyJuly 16 at 4:47 AM | durangoherald.comDWhy Aviation Buffs Still Love the F-111 AardvarkJuly 16 at 4:47 AM | msn.com111 Monsoon-related Deaths In Pakistan Since Late June: Disaster AgencyJuly 14 at 11:31 AM | barrons.com111 (NASDAQ:YI) Earns "Sell (D-)" Rating from Weiss RatingsJuly 14 at 2:28 AM | marketbeat.comSensex drops 398.45 points; Nifty declines 111.25 points in early tradeJuly 11, 2025 | deccanherald.comDISSER reports 92% completion rate for Agenda 111 health projectJuly 11, 2025 | msn.comTexas flooding: 111 confirmed dead, 161 missing in Kerr CountyJuly 11, 2025 | wpxi.comWSensex drops 398 points to 82,791 in early trade; Nifty declines 111 points to 25,244July 11, 2025 | telegraphindia.comTE-bike rider seriously hurt in Trumbull crash that closed Route 111 for hours, police sayJuly 11, 2025 | registercitizen.comR111 (YI) vs. Its Peers Critical AnalysisJuly 11, 2025 | americanbankingnews.comWith S. 111 Of BNSS Covering 'Organised Crime', Hasn't Gangsters Act Become Redundant? Allahabad HC Asks UP GovtJuly 10, 2025 | livelaw.inLF-111 Walkaround (HARS Museum)July 10, 2025 | msn.comIntersection of Highway 111 and Washington St. in La Quinta to close July 30 through 31 for paving projectJuly 9, 2025 | kesq.comKHighway 111 project in La Quinta underway, what you need to knowJuly 9, 2025 | kesq.comKNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy Wall Street Is Betting on These 3 Comeback StocksBy Nathan Reiff | July 12, 2025View Why Wall Street Is Betting on These 3 Comeback StocksTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts LoomThese 3 Dividend Stocks Combine Strong Yields With UpsideBy Chris Markoch | June 20, 2025View These 3 Dividend Stocks Combine Strong Yields With UpsideMicron Insiders Sell But Investors Should Buy, Buy, BuyBy Thomas Hughes | July 7, 2025View Micron Insiders Sell But Investors Should Buy, Buy, BuyASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideBy Gabriel Osorio-Mazilli | June 25, 2025View ASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideHCAQ, IKNA, YI, and CTSO Company DescriptionsCytosorbents NASDAQ:CTSO$0.99 -0.05 (-4.81%) Closing price 04:00 PM EasternExtended Trading$1.04 +0.05 (+5.45%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.HealthCor Catalio Acquisition NASDAQ:HCAQHealthCor Catalio Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in New York, New York.Ikena Oncology NASDAQ:IKNA$1.26 -0.03 (-2.33%) Closing price 04:00 PM EasternExtended Trading$1.25 -0.01 (-0.40%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.111 NASDAQ:YI$7.54 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$7.54 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
